Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.
Anticancer drugs can induce cardiotoxicity; the dilated cardiomyopathy secondary to chemotherapy is more insidious than various cardiomyopathies: 40% of the patients under anthracyclines treatment manifest ventricular arrhythmias, 5% of them manifest left ventricular systolic dysfunction and Congestive Heart Failure. For these patients at high cardiotoxic risk it is therefore very important to prevent cardiovascular damage.
Our mission: To reduce the burden of cardiovascular disease.